43 related articles for article (PubMed ID: 34592353)
1. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
[TBL] [Abstract][Full Text] [Related]
2. Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
Karelia DN; Kim S; Plano D; Sharma AK; Jiang C; Lu J
Prostate; 2023 Jan; 83(1):16-29. PubMed ID: 35996318
[TBL] [Abstract][Full Text] [Related]
3. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
[TBL] [Abstract][Full Text] [Related]
4. HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals.
Večeřa J; Bártová E; Krejčí J; Legartová S; Komůrková D; Rudá-Kučerová J; Štark T; Dražanová E; Kašpárek T; Šulcová A; Dekker FJ; Szymanski W; Seiser C; Weitzer G; Mechoulam R; Micale V; Kozubek S
J Cell Physiol; 2018 Jan; 233(1):530-548. PubMed ID: 28300292
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.
El Omari N; Bakrim S; Khalid A; Abdalla AN; Almalki WH; Lee LH; Ardianto C; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Aug; 164():114886. PubMed ID: 37224752
[TBL] [Abstract][Full Text] [Related]
6. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Jung-Hynes B; Nihal M; Zhong W; Ahmad N
J Biol Chem; 2009 Feb; 284(6):3823-32. PubMed ID: 19075016
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Chou YW; Chaturvedi NK; Ouyang S; Lin FF; Kaushik D; Wang J; Kim I; Lin MF
Cancer Lett; 2011 Dec; 311(2):177-86. PubMed ID: 21862211
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.
Dias JNR; Aguiar SI; Pereira DM; André AS; Gano L; Correia JDG; Carrapiço B; Rütgen B; Malhó R; Peleteiro C; Goncalves J; Rodrigues CMP; Gil S; Tavares L; Aires-da-Silva F
Oncotarget; 2018 Jun; 9(47):28586-28598. PubMed ID: 29983882
[TBL] [Abstract][Full Text] [Related]
10. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
Lee JI; Nian H; Cooper AJ; Sinha R; Dai J; Bisson WH; Dashwood RH; Pinto JT
Cancer Prev Res (Phila); 2009 Jul; 2(7):683-93. PubMed ID: 19584079
[TBL] [Abstract][Full Text] [Related]
11. Plasticity of gene expression in the nervous system by exposure to environmental odorants that inhibit HDACs.
Haga-Yamanaka S; Nunez-Flores R; Scott CA; Perry S; Chen ST; Pontrello C; Nair MG; Ray A
Elife; 2024 Feb; 12():. PubMed ID: 38411140
[TBL] [Abstract][Full Text] [Related]
12. Profile of panobinostat and its potential for treatment in solid tumors: an update.
Anne M; Sammartino D; Barginear MF; Budman D
Onco Targets Ther; 2013; 6():1613-24. PubMed ID: 24265556
[TBL] [Abstract][Full Text] [Related]
13. Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.
Mora-Rodríguez JM; Sánchez BG; Sebastián-Martín A; Díaz-Yuste A; Sánchez-Chapado M; Palacín AM; Sánchez-Rodríguez C; Bort A; Díaz-Laviada I
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958610
[TBL] [Abstract][Full Text] [Related]
14. Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells.
Rana Z; Tyndall JDA; Hanif M; Hartinger CG; Rosengren RJ
Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33572730
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Pratap UP; Sareddy GR; Liu Z; Venkata PP; Liu J; Tang W; Altwegg KA; Ebrahimi B; Li X; Tekmal RR; Viswanadhapalli S; McHardy S; Brenner AJ; Vadlamudi RK
Neurooncol Adv; 2021; 3(1):vdab099. PubMed ID: 34485908
[TBL] [Abstract][Full Text] [Related]
16. USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3.
Zhan W; Liao X; Liu J; Tian T; Yu L; Li R
Oncogenesis; 2020 May; 9(5):48. PubMed ID: 32404892
[TBL] [Abstract][Full Text] [Related]
17. Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features.
Knowles DA; Bouchard G; Plevritis S
PLoS Comput Biol; 2019 May; 15(5):e1006743. PubMed ID: 31136571
[TBL] [Abstract][Full Text] [Related]
18. Preparation of polypeptide-metal complexes-coated Hosenkoside A and its inhibitory effect in cervical cancer.
Wang Y; Lou C; Zhao S; Li B; Zhang Y; Yu Z; Wu F; Chen D; Wu Q
Int J Biol Macromol; 2024 Feb; 259(Pt 1):129177. PubMed ID: 38176488
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer.
Nguyen T; Sridaran D; Chouhan S; Weimholt C; Wilson A; Luo J; Li T; Koomen J; Fang B; Putluri N; Sreekumar A; Feng FY; Mahajan K; Mahajan NP
Nat Commun; 2023 Sep; 14(1):6022. PubMed ID: 37758702
[No Abstract] [Full Text] [Related]
20. The role of protein acetylation in carcinogenesis and targeted drug discovery.
Yang J; Song C; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972312. PubMed ID: 36171897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
